Michael Schmidt Guggenheim Securities, LLC, Research Division. All right. So daraxonrasib, obviously, there's been a lot of focus on the upcoming phase. The first randomized Phase ...

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Revolution Medicines (RVMD). The reason why I want to go over this biotech next is because ...

Phil Sharp reveals how his RNA discovery is transforming biology. A groundbreaking look at Phil Sharp's rise from being a rural Kentucky farm boy who battled dyslexia to Nobel Prize-winning scientist.

Follow Phil Sharp’s journey from Kentucky farm boy with dyslexia to Nobel Prize–winning scientist whose RNA discovery launched a biotechnology revolution. Narrated by Mark Ruffalo. Watch Independent ...

AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter, in what would be one of the year’s first megadeals. A deal could come ...

Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. The Wall Street Journal report on Wednesday noted Revolution had drawn ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...